Cancer Drugs news from FierceBiotech
News
Bayer strikes deal for Nycomed cancer therapies
A Swiss company's decision to drop its cancer programs will help Bayer beef up its oncology pipeline. Bayer has agreed to buy Nycomed's preclinical cancer therapies in a deal worth up to €52 Read more...
Genetic mutation will narrow target cancer groups
The K-ras gene is coming in for some star treatment at the ASCO meeting in Chicago. The gene plays a key role in several cancers, and new research indicates that the common genetic mutation makes Read more...
Pfizer gets new cancer team to advance key drugs
With the clock ticking on its patent for Lipitor, Pfizer has turned to a group of new executives to Read more...
Abraxis buys Shimoda, subsidiary
Abraxis BioScience has completed acquisition of South Africa's Shimoda Biotech and its subsidiary, Platco Technologies. Abraxis bought the companies for $15 million up-front, plus potential Read more...
Pfizer halts Phase III cancer trial on poor results
Pfizer's big push into cancer drugs has hit a snag. The company announced that it is halting a late-stage trial of tremelimumab for advanced melanoma after researchers concluded it was no more Read more...
Cephalon paying $10M in cancer tech deal
Cephalon is paying out $10 million to acquire the IP rights to Acusphere's Hydrophobic Drug Delivery Read more...
Avanti launches bionano company
Avanti Therapeutics launched a new bionanotechnology company for targeted drug delivery called Chikujee Therapeutics. Chikujee will use Avanti's drug delivery technology to enhance the performance of Read more...
NJ officials want to expand biopharma biz
A state economist for New Jersey has spelled out some of the biggest threats to the Garden State's biopharma industry. In a recent address, James Hughes underscored that New Jersey is losing its Read more...
ALSO NOTED: Neurochem pursues new Kiacta trial; Teva drug fails ALS trial; Columbus tapped as promising new life sciences hub;
> Neurochem is forging ahead with plans to launch a new late-stage trial for Kiacta in a renewed bid for regulatory approval. Regulators had declined to approve the amyloidosis therapy, saying Read more...
ALSO NOTED: Manhattan Pharma closes JV deal; Abbott, Genentech, WEHI in cancer collaboration; and much more...
> Manhattan Pharmaceuticals has closed on its joint venture agreement with Nordic Biotech Venture Fund II K/S to develop and commercialize Hedrin for head lice for the North American market. Read more...
Get more Cancer Drugs coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets